Loading clinical trials...

Online Peer Networked Collaborative Learning for Managing Depressive Symptoms | Clinical Trials | Clareo Health

COMPLETEDNA

Online Peer Networked Collaborative Learning for Managing Depressive Symptoms

Technology Assisted Intervention for the Treatment and Prevention of Depression

NCT02841787•Northwestern University

Summary

The goal of this field trial is to tailor and test a web-based intervention in adults 65 years of age or older. Two versions of the web-based intervention have been created and will be tested--one with an online social network and one without an online social network. The purpose of this study is to: pilot a novel intervention, examine methods to improve adherence to web-based interventions (e.g., peer network); collect data on feasibility, acceptability, and efficacy of an web-based intervention for late life depression; and ultimately, to overcome the numerous barriers to treating depression in later life.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Has elevated depressive symptoms
•Has a telephone, e-mail account, computer, and broadband access to the Internet.
•Has basic internet skills and is able to access the internet independently
•Is able to speak and read English.
•Is at least 65 years of age.
•Is able to give informed consent.

Exclusion Criteria

•Has hearing or voice impairment that would prevent participation in psychotherapy
•Has visual impairment that would prevent completion of assessment materials.
•Is diagnosed with a psychotic disorder, bipolar disorder, dissociative disorder, current substance abuse, or other diagnosis for which participation in a clinical trial of psychotherapy may be either inappropriate or dangerous.
•Is currently receiving individual psychotherapy or planning to receive psychotherapy during the 8-week treatment phase of the study
•Is planning to be out of town or unavailable for an extended period of time during the study without access to the Internet
•Exhibits severe suicidality, including ideation, plan, and intent.
•Has initiated treatment with an antidepressant in past 14 days. Once patients have been on a stable dose for 14 days and do not have an appointment with a physician or psychiatrist to change this dose, the patient will be eligible based on this criterion.

Locations (1)

Northwestern University

Chicago, Illinois, United States

Key Dates

Start Date

December 1, 2015

Primary Completion Date

August 1, 2016

Completion Date

September 1, 2016

Last Updated

October 29, 2018

Enrollment

ACTUAL participants

Conditions

Depression

Interventions

iCBT for late life depression

BEHAVIORAL

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

NCT07360600

ParentsChildren With Disabilities+2 more

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 29, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Online Peer Networked Collaborative Learning for Managing Depressive Symptoms

Inclusion Criteria

Exclusion Criteria

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures